SABCS 2024: New Research Assesses iCAD's Image Based AI-Risk, Detection, and Breast Arterial Calcifications (BAC) Assessment Across Diverse Populations

Stock Information for iCad Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About iCad Inc.

iCAD Reports Financial Results for Fourth Quarter and Fiscal Year Ended December 31, 2024
iCAD to Report Fourth Quarter and Full Year 2024 Financial Results on March 19, 2025
iCAD and RamSoft Announce Partnership to Deliver ProFound® AI-Powered Mammography Solutions Across North America
Koios Medical and iCAD Partner to Expand AI-Powered, Multi-Modality Breast Cancer Detection Solutions at ECR 2025
iCAD To Showcase Five AI-Powered Research Presentations Advancing Breast Cancer Detection, Risk Evaluation, and Breast Arterial Calcification Assessment at ECR 2025
iCAD Pre-Announces Estimated Q4 2024 Revenue
CORRECTION - iCAD Advances Fight Against Breast Cancer with FDA-cleared, Next-Generation AI Solutions and ProFound Health Partnership with Cascaid Health at RSNA 2024
iCAD Advances Fight Against Breast Cancer with FDA-cleared, Next-Generation AI Solutions and a Second-Read AI Partnership with Cascaid Health at RSNA 2024

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.